VENTOLIN HFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENTOLIN HFA (VENTOLIN HFA).
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP, leading to relaxation of bronchial smooth muscle.
| Metabolism | Primarily metabolized by sulfotransferase (SULT1A3) to an inactive sulfate conjugate; minor metabolism by COMT and MAO. |
| Excretion | Renal (60-70% as unchanged drug and metabolites, primarily as sulfate conjugate; biliary/fecal: minor, <10%). |
| Half-life | 3-4 hours for systemically absorbed albuterol; terminal half-life is approximately 3.8 hours. No accumulation with repeated dosing. |
| Protein binding | ~10% (primarily to albumin). |
| Volume of Distribution | 1.9-2.5 L/kg (indicating extensive extravascular distribution). |
| Bioavailability | Inhalation: 20-30% (systemic absorption via lungs and swallowed fraction). Oral: ~50% (but not used orally due to systemic effects). |
| Onset of Action | Inhalation: 5-15 minutes (rapid bronchodilation). |
| Duration of Action | 4-6 hours (dose-dependent; shorter in some patients with severe bronchospasm). |
| Molecular Weight | 576.6 |
90 mcg (2 inhalations) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment required for renal impairment. The primary route of elimination is hepatic metabolism. |
| Liver impairment | No specific dose adjustment guidelines for hepatic impairment. Use with caution in severe hepatic disease as albuterol clearance may be reduced. |
| Pediatric use | Children 4 years and older: 90 mcg (2 inhalations) by oral inhalation every 4 to 6 hours as needed. For exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise. Children 2 to 4 years: Safety and efficacy not established for this age group. |
| Geriatric use | No specific dose adjustment recommended for elderly patients. Monitor for excessive tachypnea, tachycardia, or other side effects, as elderly patients may have increased sensitivity to beta-2 agonists. |
| 1st trimester | Limited human data; animal studies show no teratogenic effects. Use only if benefit outweighs risk. |
| 2nd trimester | Generally considered safe; monitor maternal asthma control. |
| 3rd trimester | May cause fetal tachycardia or hypoglycemia if used near term; use with caution. |
Clinical note
Comprehensive clinical and safety monograph for VENTOLIN HFA (VENTOLIN HFA).
| Placental transfer | Crosses placenta; extent unknown but likely limited due to high ionization and polarity. |
| Breastfeeding | Excreted in breast milk in small amounts; no adverse effects reported in infants. Use with caution in preterm or jaundiced infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to albuterol or any component
| Precautions | Paradoxical bronchospasm may occur, Cardiovascular effects: increased heart rate, hypertension, arrhythmias, Hypokalemia may occur, Monitor for signs of hypersensitivity reactions |
| Food/Dietary | No specific food interactions. However, avoid excessive caffeine intake (e.g., coffee, tea, energy drinks) as it may increase risk of nervousness, tremor, or palpitations. Limit alcohol consumption as it may exacerbate side effects like dizziness. |
| Clinical Pearls |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | Albuterol (VENTOLIN HFA) is FDA Pregnancy Category C. In animal studies, albuterol administered subcutaneously caused fetal abnormalities (cleft palate, limb defects) at high doses (0.25-2.5 mg/kg). However, among pregnant women, inhaled albuterol has not been shown to increase the risk of major congenital malformations. Hypoglycemia and/or tachycardia may occur in the neonate after maternal use of beta-2 agonists, particularly with high doses or prolonged use near term. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of pulmonary edema in patients with preeclampsia or cardiovascular disease. Fetal monitoring (non-stress test or biophysical profile) may be considered if used for preterm labor or in cases of maternal tachycardia or hypoxia. |
| Fertility Effects | No adverse effects on fertility have been reported in human studies. In animal studies, albuterol did not impair fertility at doses up to 50 times the maximum human inhalation dose. |
| VENTOLIN HFA (albuterol sulfate) is a short-acting beta-2 agonist used for acute relief of bronchospasm. Priming: prime with 4 test sprays before first use or if not used for >2 weeks. Shake well before each use. Rinse mouth after inhalation to prevent candidiasis. Monitor for paradoxical bronchospasm, hypokalemia, and increased heart rate. Consider spacer device for improved lung deposition, especially in children or elderly. Not for maintenance therapy in asthma; use with inhaled corticosteroids for persistent asthma. |
| Patient Advice | Use exactly as prescribed; do not exceed 12 inhalations in 24 hours. · Prime inhaler before first use or if not used for more than 2 weeks. · Shake well for 5 seconds before each spray. · Rinse mouth with water after each use to prevent throat irritation and oral thrush. · Seek emergency care if symptoms worsen or if you need more than 12 inhalations in a day. · Store at room temperature away from extreme heat or cold; do not puncture or burn canister. · Carry your inhaler at all times for sudden breathing problems. |